HomeCompareSSUMY vs ABBV

SSUMY vs ABBV: Dividend Comparison 2026

SSUMY yields 1.15% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $32.9K in total portfolio value
10 years
SSUMY
SSUMY
● Live price
1.15%
Share price
$39.10
Annual div
$0.45
5Y div CAGR
54.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$21,405.82
Full SSUMY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SSUMY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSUMYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSUMY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSUMY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSUMY
Annual income on $10K today (after 15% tax)
$98.03/yr
After 10yr DRIP, annual income (after tax)
$18,194.95/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $2,861.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSUMY + ABBV for your $10,000?

SSUMY: 50%ABBV: 50%
100% ABBV50/50100% SSUMY
Portfolio after 10yr
$85.9K
Annual income
$23,088.79/yr
Blended yield
26.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SSUMY
No analyst data
Altman Z
1.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSUMY buys
0
ABBV buys
0
No recent congressional trades found for SSUMY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSUMYABBV
Forward yield1.15%3.06%
Annual dividend / share$0.45$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.2%40.6%
Portfolio after 10y$69.4K$102.3K
Annual income after 10y$21,405.82$24,771.77
Total dividends collected$45.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSUMY vs ABBV ($10,000, DRIP)

YearSSUMY PortfolioSSUMY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,878$177.84$11,550$430.00$672.00ABBV
2$11,918$278.79$13,472$627.96$1.6KABBV
3$13,193$440.19$15,906$926.08$2.7KABBV
4$14,818$702.21$19,071$1,382.55$4.3KABBV
5$16,992$1,136.67$23,302$2,095.81$6.3KABBV
6$20,060$1,878.40$29,150$3,237.93$9.1KABBV
7$24,660$3,195.74$37,536$5,121.41$12.9KABBV
8$32,048$5,661.52$50,079$8,338.38$18.0KABBV
9$44,894$10,603.21$69,753$14,065.80$24.9KABBV
10$69,443$21,405.82$102,337$24,771.77$32.9KABBV

SSUMY vs ABBV: Complete Analysis 2026

SSUMYStock

Sumitomo Corporation engages in general trading business worldwide. It operates through six segments: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics. The company provides steel sheets and tubular products; and manufactures, leases, sells, services, and finances ships, aircrafts, motor vehicles, construction equipment, and components and parts. It is also involved in the development of renewable energy projects comprising power generation and power plant engineering, procurement, and construction activities; electricity retail; industrial facilities and equipment, water, transportation systems and infrastructure, airports, smart city project, environmental solutions, and storage battery businesses; development and operation of industrial parks; arranging insurance; and provision of logistics services. In addition, the company engages in the cable television, 5G related technologies, programming distribution, movies, digital media and video content, TV shopping, and e-commerce businesses; cell phone, ICT platform, digital solution, and venture capital businesses; provision of smart communications infrastructure; operation of food supermarkets and drugstore chains; trade of cement and building materials; and real estate businesses. Further, it develops and trades in coal, iron ore, manganese, uranium, non-ferrous and precious metals, petroleum, natural gas and liquefied natural gas, and commodity derivative transactions; trades in non-ferrous metal products, liquefied petroleum gas, storage batteries, carbon products, plastics, organic and inorganic chemicals, silicon wafers, LEDs, pharmaceuticals, agricultural chemicals, household insecticides, fertilizers, and veterinary drugs; engages in the investing activities; and provides electronics manufacturing services. The company was incorporated in 1919 and is headquartered in Tokyo, Japan.

Full SSUMY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SSUMY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSUMY vs SCHDSSUMY vs JEPISSUMY vs OSSUMY vs KOSSUMY vs MAINSSUMY vs JNJSSUMY vs MRKSSUMY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.